GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PharmaNutra SpA (MIL:PHN) » Definitions » LT-Debt-to-Total-Asset

PharmaNutra SpA (MIL:PHN) LT-Debt-to-Total-Asset : 0.17 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is PharmaNutra SpA LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PharmaNutra SpA's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.17.

PharmaNutra SpA's long-term debt to total assets ratio declined from Dec. 2023 (0.21) to Dec. 2024 (0.17). It may suggest that PharmaNutra SpA is progressively becoming less dependent on debt to grow their business.


PharmaNutra SpA LT-Debt-to-Total-Asset Historical Data

The historical data trend for PharmaNutra SpA's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaNutra SpA LT-Debt-to-Total-Asset Chart

PharmaNutra SpA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.08 0.14 0.21 0.17

PharmaNutra SpA Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.19 0.19 0.18 0.17

PharmaNutra SpA LT-Debt-to-Total-Asset Calculation

PharmaNutra SpA's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )/Total Assets (A: Dec. 2024 )
=19.507/117.468
=0.17

PharmaNutra SpA's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=19.507/117.468
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaNutra SpA  (MIL:PHN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


PharmaNutra SpA LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of PharmaNutra SpA's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaNutra SpA Business Description

Traded in Other Exchanges
Address
Via Campodavela 1, Pisa, ITA, 56122
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, Asia, and others.

PharmaNutra SpA Headlines

No Headlines